Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Naoki KawagishiGoki SudaAkinobu NakamuraMegumi KimuraOsamu MaeharaKazuharu SuzukiAkihisa NakamuraMasatsugu OharaTakaaki IzumiMachiko UmemuraMasato NakaiTakuya ShoMitsuteru NatsuizakaKenichi MorikawaKoji OgawaYusuke KudoMutsumi NishidaHideaki MiyoshiNaoya SakamotoPublished in: PloS one (2018)
Generally, successful HCV eradication by IFN-free-DAAs decreases CAP and LDL-C in patients with high baseline values. However, elevated LDL-C was accompanied with elevated sdLDL-C only in patients with liver steatosis and dyslipidemia at SVR24; therefore, those patients may require closer monitoring.
Keyphrases
- hepatitis c virus
- end stage renal disease
- insulin resistance
- high fat diet
- ejection fraction
- newly diagnosed
- chronic kidney disease
- helicobacter pylori infection
- cardiovascular disease
- human immunodeficiency virus
- immune response
- dendritic cells
- metabolic syndrome
- cancer therapy
- hiv infected
- human health
- patient reported